Tag: Revolving Door

“Is the FDA Too Cozy With Drug Companies?”

TIME magazine covers a new report suggesting that many medical reviewers who work for the FDA go on to work for the drug companies they...

“FDA Nominee Robert Califf Must Prove Independence from Industry”

For STAT, Ed Silverman reports on growing concerns about the industry ties of the new nominee for FDA commissioner.  “The nomination comes at a...

Lansley Joins Roche in Latest Example of ‘Revolving Door’

The BMJ reports that renewed concerns about the “revolving door” between government and industry have been sparked by the health minister of England’s decision to join to drug company Roche.

Bernie Sanders Opposes Califf for FDA Post Cites Industry Ties

Bernie Sanders joins numerous public health groups and opposes Robert Califf's nomination to lead the FDA over industry ties.

Nominee to Lead FDA Removed Name From Recent Publications

Sheila Kaplan for the Boston Globe reports that Dr. Robert Califf, the Obama administration's nominee to lead the Food and Drug Administration (FDA), has removed his name from a series of scientific papers that he recently coauthored. The decision to remove his name, against publication ethics standards, has brought Califf under renewed criticism.

Nominee for FDA Commissioner Has Strong Industry Ties

On Tuesday, the Obama administration nominated Dr. Robert Califf to be the new commissioner of the Food and Drug Administration (FDA). In a statement, director of the Public Citizen’s Health Research Group, Dr. Michael Carome called on the Senate to reject the nomination. He contends that Califf “racked up a long history of extensive financial ties to multiple drug and medical device companies, including Amgen, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck Sharp & Dohme and Sanofi-Aventis, to name a few.”